Curated News
By: NewsRamp Editorial Staff
September 04, 2025
Nutriband Secures $5.3M to Advance World's First Abuse-Deterrent Fentanyl Patch
TLDR
- Nutriband's $5.3M warrant exercise funds AVERSA Fentanyl development, positioning it as the first abuse-deterrent opioid patch with $80-200M peak annual sales potential.
- Nutriband raised $5,306,000 through warrant exercises at $6.43 per share to complete clinical trials and submit an NDA for AVERSA Fentanyl to the FDA.
- AVERSA Fentanyl's abuse-deterrent technology prevents opioid misuse and accidental exposure, making opioid therapy safer for patients and communities worldwide.
- Nutriband is developing the world's first abuse-deterrent fentanyl patch using innovative AVERSA technology to transform transdermal drug delivery safety.
Impact - Why it Matters
This development matters significantly because it addresses the ongoing opioid crisis that has devastated communities worldwide. The AVERSA Fentanyl patch represents a crucial innovation in pain management by potentially reducing opioid abuse and diversion while still providing effective relief for legitimate patients. Given that fentanyl is among the most potent and dangerous opioids, an abuse-deterrent version could save countless lives by preventing misuse that often leads to overdose deaths. For healthcare providers, this technology offers a safer alternative for managing severe chronic pain, while for society, it represents progress in balancing pain treatment needs with public health safety concerns.
Summary
Nutriband Inc. (NASDAQ: NTRB), a pioneering developer of abuse deterrent pharmaceutical products, has successfully exercised warrants at a strike price of $6.43, generating substantial proceeds of $5,306,000. These crucial funds will accelerate the remaining clinical development of their groundbreaking AVERSA Fentanyl patch and support the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration. This financial milestone positions Nutriband to potentially launch the world's first opioid patch with integrated abuse deterrent properties, addressing a critical gap in pain management and opioid safety.
The AVERSA Fentanyl patch incorporates Nutriband's proprietary AVERSA™ technology, which can be integrated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. According to a comprehensive 2022 Health Advances market analysis report, this innovative product is projected to achieve peak annual U.S. sales ranging from $80 million to $200 million, reflecting both its medical necessity and market demand. The development represents a significant advancement in the fight against the opioid crisis while providing effective pain management solutions for patients who genuinely need them.
This announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio of IBN that focuses on biotechnology and biomedical sciences. The platform provides extensive distribution networks, including access to wire solutions via InvestorWire, editorial syndication to over 5,000 outlets, enhanced press release services, and comprehensive social media distribution through IBN's massive follower base. For investors seeking the latest updates on NTRB, the company maintains an active newsroom accessible through their dedicated portal.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Secures $5.3M to Advance World's First Abuse-Deterrent Fentanyl Patch
